Plain-English translation of NCT06430684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called empagliflozin to see if it can help protect the kidneys and heart in young people with chronic kidney disease. Researchers want to learn whether it's possible to recruit enough young patients for this type of study, and whether the medication leads to improvements in blood pressure, kidney function, and heart health markers.
Chronic kidney disease in children can lead to serious heart and kidney problems over time. This medication has shown promise in adults, but researchers don't yet know if it's safe and helpful for young patients, or even if families would be willing to enroll in a study testing it.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll visit the hospital or clinic at the start and again after 3 months for health checks and blood and urine tests. Half of participants will receive the medication once daily for those 3 months, while the other half will continue their usual care. Everyone will receive phone check-ins every 2 weeks, and those taking the medication will have two additional clinic visits at 4 and 8 weeks to monitor how they're doing.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
United States